临床试验/jRCT2080220094

jRCT2080220094未知N/a

A confirmatory study of APTA-2217 in adult patients with bronchial asthma (A placebo-controlled double-blind comparative study)

Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party0 个研究点开始时间: 待定

适应症

试验速览

阶段: N/a
发起方
主要终点: -

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
干预模型: Double-blind, parallel-group comparative clinical study

入排标准

年龄范围: 20age old over 至 69age old under（—）
性别: All

入选标准

•[Inclusion criteria]
•Patient with bronchial asthma who are 20 to 70 years old, non-smoker or ex-smoker for 12 months or more, 60 to 80 % of predicted FEV1
•[Exclusion criteria]
•Patients with poorly controlled asthma, patients with a clear diagnosis of seasonal asthma and patients who have concurrent respiratory diseases such as COPD, chronic bronchitis, pulmonary emphysema, and bronchiectasis, which are judged to have an effect on the evaluation.

排除标准

未提供

结局指标

主要结局

-

Efficacy (pulmonary function test), safety and pharmacokinetics

次要结局

未报告次要终点

研究者

发起方

Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party

相似试验

A confirmatory study of APTA-2217 in adult patients with bronchial asthma (A placebo-controlled double-blind comparative study)Bronchial asthma

JPRN-jRCT2080220094Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party

A confirmatory study of APTA-2217 in patients with chronic obstructive pulmonary disease (A placebo-controlled double-blind, parallel group study)

jRCT2080220095Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party

A confirmatory study of APTA-2217 in patients with chronic obstructive pulmonary disease (A placebo-controlled double-blind, parallel group study)

JPRN-jRCT2080220095Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party

Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertensionPulmonary arterial hypertension

jRCT2080220801ASAHI KASEI PHARMA CORPORATION

Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertensioPulmonary arterial hypertension

JPRN-jRCT2080220801ASAHI KASEI PHARMA CORPORATIO